arrow
I

Ibrahim Tohidi-Esfahani

University of Sydney
H指数:9
被引数:250

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)

布鲁顿酪氨酸激酶抑制剂(BTKis)剂量中断(DIs)对华氏巨球蛋白血症(WM)患者IgM水平变化及临床结局的长期影响

BLOOD
IF23.1
2024-11-050
PRE
Real World Treatment Outcomes in the First Line Management of Waldenström Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical

真实世界下Waldenström巨球蛋白血症一线治疗管理的结果:来自全球患者衍生数据登记库Whimsical的数据

BLOOD
IF23.1
2024-11-050
PRE
Rivaroxaban for stroke patients with antiphospholipid syndrome (RISAPS): protocol for a randomized controlled, phase IIb proof-of-principle trial
2024-07-012
OAAI
SARS-CoV-2 Infection in Patients With Waldenstrom's Macroglobulinemia: A Multicenter International Cohort Study
2023-06-011
OAAI
Report of consensus panel 1 from the 11th I Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naive patients nternational Workshop on
2023-03-0116
OAAI
Report of consensus panel 2 from the 11th international workshop on Waldenstrom's macroglobulinemia on the management of relapsed or refractory WM patients
2023-03-017
OAAI
Assessment of immunological anti-platelet factor 4 antibodies for vaccine-induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: A multicenter study comprising 1284 patients
2022-12-0118
OAAI
A novel flow cytometry procoagulant assay for diagnosis of vaccine-induced immune thrombotic thrombocytopenia
2022-06-1013
OAAI